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Tumor necrosis factor (TNF) can drive inflammation,
cell survival, and death. While ubiquitylation-, phos-
phorylation-, and nuclear factor kB (NF-kB)-depen-
dent checkpoints suppress the cytotoxic potential of
TNF, it remains unclear whether ubiquitylation can
directly repress TNF-induced death. Here, we show
that ubiquitylation regulatesRIPK1’s cytotoxic poten-
tial not only via activation of downstream kinases and
NF-kB transcriptional responses, but also by directly
repressing RIPK1 kinase activity via ubiquitin-depen-
dent inactivation. We find that the ubiquitin-associ-
ated (UBA) domain of cellular inhibitor of apoptosis
(cIAP)1 is required for optimal ubiquitin-lysine occu-
pancyandK48ubiquitylationofRIPK1. Independently
of IKK and MK2, cIAP1-mediated and UBA-assisted
ubiquitylation suppresses RIPK1 kinase auto-activa-
tion and, in addition, marks it for proteasomal degra-
dation. In the absence of a functional UBA domain of
cIAP1, more active RIPK1 kinase accumulates in
response to TNF, causing RIPK1 kinase-mediated
cell death and systemic inflammatory response syn-
drome. These results reveal a direct role for cIAP-
mediated ubiquitylation in controlling RIPK1 kinase
activity and preventing TNF-mediated cytotoxicity.
INTRODUCTION
Inflammation and cell death are ancient processes of funda-
mental biological importance that enable survival and adaptation
during infection and injury. Tumor necrosis factor (TNF) is a566 Molecular Cell 69, 566–580, February 15, 2018 ª 2018 The Autho
This is an open access article under the CC BY license (http://creativepotent inflammatory cytokine that triggers, through its type 1 re-
ceptor (TNF-R1), either pro-survival/inflammatory or pro-death
signaling pathways in a ubiquitin (Ub)- and phosphorylation-
dependent manner (Annibaldi and Meier, 2018). TNF can regu-
late tissue homeostasis in at least three different ways: (1) activa-
tion of nuclear factor kB (NF-kB) and MAPK/JNK-transcriptional
programs, (2) induction of caspase-8-dependent apoptosis, or
(3) stimulation of receptor-interacting protein kinase (RIPK)-
mediated necroptosis (Declercq et al., 2009).
Binding of TNF to TNF-R1 results in the formation of two
signaling complexes (Micheau and Tschopp, 2003). Upon TNF
ligation, a protein complex assembles on the cytoplasmic tail
of TNFR1. This complex, frequently referred to as complex-I,
consists of TNF-R1, the adaptors TRADD and TRAF2, the kinase
RIPK1, and the E3 ubiquitin (Ub) ligases cellular inhibitor of
apoptosis 1 (cIAP1) and cIAP2 (Silke, 2011; Ting and Bertrand,
2016). Within this complex, RIPK1 and other proteins are rapidly
conjugated with M1, K11, K48, and K63 Ub linkage types (Don-
delinger et al., 2016; Dynek et al., 2010; Gerlach et al., 2011; Pelt-
zer et al., 2016), and cIAP-mediated conjugation of Ub to RIPK1
allows recruitment of the kinase complex TAK1/TAB2/TAB3 and
the E3 ligase linear Ub chain assembly complex (LUBAC,
composed of HOIL/HOIP/SHARPIN). LUBAC-mediated linear
ubiquitylation of different components of complex-I (RIPK1,
TRADD, and TNF-R1) subsequently reinforces complex-I and
allows efficient recruitment and activation of IKK (composed of
NEMO/IKKa/IKKb), which in turn drives activation of NF-kB
(Zinngrebe et al., 2014). While the synthesis of M1- and K63-
linked poly-Ub chains play key roles in Ub-dependent assembly
of complex-I and the induction of NF-kB target genes that drive
inflammation and cell survival following TNF stimulation, the role
of K11 and K48 poly-Ub remains largely uncharacterized.
TNF-induced cell death is mediated by an RIPK1-containing
secondary complex that is frequently referred to as complex-II
or necrosome (Micheau and Tschopp, 2003; Pasparakis andr(s). Published by Elsevier Inc.
commons.org/licenses/by/4.0/).
Vandenabeele, 2015; Wang et al., 2008). It is thought that the
Ub chains conjugated to RIPK1 by cIAP1/2 and LUBAC in
complex-I constitute one of the decisive factors preventing
RIPK1 from forming complex-II and limiting its killing potential
(Bertrand et al., 2008; Haas et al., 2009; Peltzer et al., 2016).
Consistently, genetic deletion of cIAPs completely abrogates
RIPK1 ubiquitylation, leading to exaggerated complex-II for-
mation and RIPK1-mediated cell death in response to TNF
(Moulin et al., 2012). The interpretation of the role of RIPK1
ubiquitylation in suppressing the cytotoxic potential of RIPK1
is complicated by the fact that loss of cIAPs not only abro-
gates RIPK1 ubiquitylation, but also interferes with recruitment
of LUBAC, TAK1, and IKK. In particular, loss of TAK1 recruit-
ment prevents activation of MK2 and IKK, which in turn regu-
late the cytotoxic potential of RIPK1 via direct phosphorylation
(Dondelinger et al., 2015, 2017; Jaco et al., 2017; Menon et al.,
2017). Thus, loss of cIAPs not only interferes with activation
of NF-kB, but also abrogates MK2- and IKK-mediated sup-
pression of RIPK1 (Bettermann et al., 2010; O’Donnell et al.,
2007; Vandenabeele and Bertrand, 2012).
While it is beyond doubt that cIAPs suppress TNF-induced cell
death, how this is achieved remains unclear. The main problem
in dissecting cIAP-mediated regulation of TNF-induced cell
death has been the fact that the signaling aspect of Ub (recruit-
ment/activation of TAK1, IKK, MK2, and NF-kB-mediated gene
induction) and the direct Ub-dependent anti-apoptotic function
of cIAPs cannot be separated. We now identified a point
mutation in cIAP1 that selectively sensitizes cells to TNF-
induced cell death, without interfering with TNF-mediated acti-
vation of NF-kB, and IKK- and MK2-mediated phosphorylation
of RIPK1. This mutation affects the evolutionarily conserved
ubiquitin-associated (UBA) domain of cIAP1. Mice with a
knockin mutation in the UBA domain develop normally but are
acutely sensitive to TNF-induced systemic inflammatory
response syndrome (SIRS), which is caused by enhanced sensi-
tivity to TNF-mediated cell death. Our data are consistent with
the notion that the UBA domain is required for Ub-mediated
regulation of RIPK1 kinase activity. We find that cIAP1 represses
RIPK1 kinase auto-activation via UBA-dependent ubiquitylation
of an expanded repertoire of Ub-acceptor lysines of RIPK1. In
addition, we find that cIAP1 with a functional UBA domain in-
creases the number of ubiquitylation sites on RIPK1. Moreover,
it enhances K48-linked poly-ubiquitylation of RIPK1. Together,
this destabilizes active RIPK1 via proteasomal degradation. In
the absence of a functional UBA domain, fewer K residues are
ubiquitylated and fewer K48-linked chains are present on
RIPK1. Together, this causes lethal accumulation of active
RIPK1 kinase in response to TNF in cIAP1UBAmut cells. Our
data demonstrate that cIAP-mediated ubiquitylation of RIPK1
directly regulates its kinase activity, independently of the recruit-
ment of IKK and TAK1 kinase complexes.
RESULTS
Multivalent Interactions between cIAP1 and TRAF2
The BIR1 and RING domains of cIAP1/2 are required for TNF
signaling, but little is known about the role of the UBA domain.
Because UBA domains often regulate protein activity via pro-tein-protein interactions (Dikic et al., 2009; Hicke et al., 2005;
Yagi et al., 2012), we conducted a yeast two-hybrid experiment
with the UBA containing C-terminal portion of cIAP1 (cIAP1U/C/R)
to establish a UBA interactome of cIAP1 (Figures 1A and 1B).
This identified known as well as novel cIAP1-binding proteins
(Figure 1B). Surprisingly, out of the 137 clones identified,
TRAF2 was isolated 107 independent times. While previous
work established that TRAF2 binds to the BIR1 of cIAP1 and
cIAP2 (Samuel et al., 2006; Vince et al., 2009; Zheng et al.,
2010) (Figure 1A), our data suggest that TRAF2 also associates
with the C-terminal portion of cIAP1.
To narrow down the region within the UBA-CARD-RING frag-
ment that mediates TRAF2 binding, we determined the ability of
truncation mutants to interact with TRAF2. The UBA domain
readily interacted with TRAF2 (Figures 1C and S1A), and point
mutations in the conserved MGF motif of the hydrophobic patch
of the UBA domain (MF > AA) abrogated TRAF2 binding. Consis-
tent with the notion that cIAP1 binds TRAF2 through multivalent
interactions via its BIR1 as well as UBA domains, we found that
point mutations in either the BIR1 (ER > AA) or UBA (MF > AA) did
not abolish the interaction between cIAP1 and TRAF2 in yeast
two-hybrid experiments (Figures 1D, 1E, and S1B).
We next mapped the region of TRAF2 that bound to the UBA
domain. Surprisingly, the cIAP-interacting motif (CIM) in the
TRAF-N domain, which is required for TRAF2 to interact with
the BIR1 of cIAP1 (Vince et al., 2009), was also indispensable
for UBA binding. Accordingly, deletion of the CIM completely
abrogated the interaction between TRAF2 and the UBA
domain of cIAP1 (Figures 1F and S1C). These data indicate
that cIAP1 contains two surfaces on very distinct spatially
separated domains that bind to the same short TRAF2 motif.
Because TRAF2 forms trimers (Zheng et al., 2010), we cannot
discern whether the UBA and BIR1 bind to the very same CIM
of one TRAF2 molecule or to different CIMs of adjacent
molecules.
The UBA Contributes to TRAF2 Binding in Solution and
in Cells
To independently corroborate the interaction, we performed
isothermal titration calorimetry (ITC) using recombinant cIAP2.
cIAP2 was used instead of cIAP1 because structural information
of TRAF2/cIAP2 is available, and previous ITC measurements
indicate that the BIR1 domains of cIAP1 and cIAP2 bind
TRAF2 equivalently (Zheng et al., 2010). Of note, cIAP1’s UBA
is 87% similar to that of cIAP2. While the interaction between
TRAF2 and the BIR1 domain of cIAP2 exhibits a dissociation
constant of 1.7 mM (Zheng et al., 2010), we found that the BIR1
in conjunction with the UBA domain bound to TRAF2 with a
significantly higher affinity (0.43 mM) (Figures 2A and 2B). The
increase in affinity can be explained by direct binding of
the UBA domain to TRAF2, with a dissociation constant of
0.48 mM (Figure 2C).
To determine the importance of the UBA domain for
TRAF2 binding, we used Flp-InTM-RexTM-HEK293 (referred to
as Flp-In) cells. Prior to transgene insertion, isogenic parental
HEK293Flp-In;shcIAP1 cells bearing a doxycycline-inducible
mir30-based short hairpin RNA (shRNA) against the 30 UTR of
endogenous cIAP1were generated and reconstituted with eitherMolecular Cell 69, 566–580, February 15, 2018 567
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Figure 1. The UBA Domain of cIAP1 Interacts with TRAF2
(A) Schematic representation of the domain architecture of cIAPs and TRAF2, and the interaction between cIAPs and TRAF2.
(B) Schematic representation of the putative interaction partners of cIAP1, identified by yeast two-hybrid using the C-terminal portion (encompassing the
UBA/CARD/RING region) of cIAP1 as bait.
(C–F) Yeast two-hybrid analysis studying the interaction between the indicated cIAP1 fragments and TRAF2 variants. Three single colonies for each
cotransformation grown on nonselective (SD-Leu-Trp) or selective medium (SD-Leu-Trp-His, containing the indicated 3AT concentration) are shown.wild-type (WT) cIAP1 or the indicated mutants (Figure 2D).
Because HEK293Flp-In cells do not express detectable levels of
cIAP2 (data not shown), this system ensures single-copy inser-
tion and equal expression levels of untagged cIAP1 proteins
without interference from endogenous cIAPs. Expression of
the doxycycline-inducible cIAP1 shRNA in parental cells
reduced cIAP1 to an almost undetectable level and resulted in
concomitant activation of the non-canonical NF-kB pathway
(Figure 2E). Cells reconstituted with either a WT or a UBAmutant
version of cIAP1 exhibited comparable levels of cIAP1, indi-
cating that the UBA mutation did not affect protein stability.
Moreover, cIAP1MF > AA suppressed activation of the non-canon-
ical NF-kB pathway (Figure 2E) and underwent SMAC mimetic
(SM)-induced auto-ubiquitylation and degradation, indicating
that cIAP1MF > AA is able to ubiquitylate NIK and itself. Bio-568 Molecular Cell 69, 566–580, February 15, 2018tinylated SM readily co-purified TRAF2 with WT cIAP1 (Fig-
ure 2F). In contrast, and consistent with earlier reports (Samuel
et al., 2006; Vince et al., 2009; Zheng et al., 2010), we found
that mutation of the BIR1 (cIAP1ER > AA) almost completely abol-
ished the binding of cIAP1 to TRAF2 (Figure 2F). Interestingly,
mutation of the UBA domain, via either alteration of the
MGF motif (MF > AA) or substitutions of E401 and N428 to RR
(EN > RR), which disrupt UBA-mediated protein:protein interac-
tions (Budhidarmo and Day, 2014), likewise impaired
TRAF2 binding (Figures 2F and 2G). While cIAP1-BIR1ER > AA
and -UBAMF > AA mutants retained some binding to TRAF2, com-
bined mutation (ER > AA/MF > AA) completely abrogated the
interaction between cIAP1 and TRAF2 (Figure 2F). Together,
these data corroborate the notion that TRAF2 interacts with
cIAP1 via its BIR1 and UBA domain.
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The UBA Domain Is Dispensable for Development and
Regulation of NF-kB
To study the function of the UBA domain of cIAP1 in vivo, we
generated a conditional knockinmouse bearing theMF >AAmu-
tation in the absence of cIAP2 (Figure 3A). Previous work indi-
cated that cIAP1 and cIAP2 function redundantly to each other
(Conte et al., 2006; Conze et al., 2005;Moulin et al., 2012). There-
fore, we generated the conditional cIAP1UBAmut mouse from an
embryonic stem cell (ESC) clone that previously had been tar-
geted at the cIAP2 locus (Moulin et al., 2012). These doubly tar-
geted animals (cIAP2/cIAP1UBAmut) are subsequently referred
to as cIAP1UBAmut. cIAP1UBAmut mice were weaned at the ex-
pected Mendelian ratio (Figure 3B) and were indistinguishable
from their WT counterparts (Figures S2A and S2B). Additionally,
these mice had an overtly normal immune system (Figure S2C).
Primary mouse embryonic fibroblasts (MEFs) from WT and
cIAP1UBAmut embryonic day 13.5 (E13.5) embryos exhibited the
same cIAP1 protein levels (Figure 3C), indicating that the UBA
mutation had no impact on the stability of cIAP1. As expected,
these cells exhibited undetectable levels of cIAP2 mRNA (Fig-
ure S2D). To verify whether the UBA mutation affected cIAP1’s
E3 ligase function, we tested the ability of SM to stimulate
auto-ubiquitylation and degradation of cIAP1UBAmut. We found
that the behavior of cIAP1UBAmut was indistinguishable from its
WT counterpart (Figure S2E).
To test the binding of cIAP1UBAmut to TRAF2, we purified cIAP1
using biotinylated SM. Significantly less TRAF2 was co-purified
with cIAP1 in cIAP1UBAmut cells, while no TRAF2 binding was
observed in TRAF2/ cells (Figure 3D). Importantly, however,
while this immunoprecipitation (IP) setting reveals a weakened
association between cIAP1UBAmut and TRAF2, cIAP1UBAmut
and TRAF2 are perfectly capable of interacting with each other
in a physiological meaningful way because the UBA mutation
of cIAP1 does not phenocopy loss of TRAF2 (Figure 3E). Accord-
ingly, RIPK1 is readily poly-ubiquitylated in complex-I from
cIAP1UBAmut cells, while RIPK1 ubiquitylation was lost in Traf2
knockout (KO) cells (Figure 3E). Moreover, cIAP1:TRAF2-medi-
ated regulation of NIK, and suppression of non-canonical
NF-kB, was normal in cIAP1UBAmut cells (Figure 3F). In contrast,
depletion of cIAP1WT and cIAP1UBAmut by SM or depletion of
TRAF2 by TWEAK activated (Vince et al., 2008) non-canonical
NF-kB (Figure 3F). As TRAF2 is essential to bring cIAPs to NIK,
these data demonstrate that cIAP1UBAmut:TRAF2 association is
sufficiently strong in vivo to target NIK for degradation. Addition-
ally, a functional UBA domain of cIAP1 was dispensable forFigure 2. cIAP2 Requires a Functional UBA Domain to Efficiently Inter
(A–C) Binding of the indicated cIAP2 fragments to TRAF2 was measured by isothe
from Zheng et al. (2010) and are shown for the purposes of comparison only.
(D) Schematic diagram of the Flp-InTMT-RExTM-HEK293shcIAP1 cell system in
mir30-based shRNA targeting cIAP1’s 30 UTR. These cells also carry a single FR
scriptionally regulatable genomic locus. Expression of the transgene and themir3
tetracycline response element; UBC, ubiquitin promoter; FRT, flippase recognit
reverse Tet transactivator (rtTA3).
(E) Western blot analysis of Flp-In cells treated for 72 hr with Dox (100 ng/mL), to
SMAC mimetic (SM) compound A (100 nM) for 6 hr.
(F and G) Biotinylated SM was used to purify IAPs from lysates of Flp-In cells
immunoblotting. In parallel, expression levels of cIAP1 and TRAF2 were controll
sentative immunoblots are shown of three independent experiments.
570 Molecular Cell 69, 566–580, February 15, 2018timely TNF-induced phosphorylation of p65, degradation of
IkB, phosphorylation of MAPKs (Figures 3G and S2F), and the
production of cytokines in primary MEFs, bone marrow-derived
macrophages (BMDMs), and keratinocytes (Figures 3H–3K).
Taken together, our data demonstrate that cIAP1UBAmut retains
E3 ligase activity, and a functional UBA domain is dispensable
for embryonic development or routine tissue homeostasis. Addi-
tionally, we conclude that a functional UBA domain of cIAP1 is
not required for Ub-dependent formation of complex-I, activa-
tion of the canonical NF-kB pathway, and suppression of non-
canonical NF-kB signaling.
cIAP1UBAmut Mice Develop Normally but Are Acutely
Sensitive to TNF-Induced Systemic Inflammatory
Response Syndrome
Next, we tested the response of cIAP1UBAmut mice to TNF chal-
lenge. Injection of TNF provokes systemic inflammation that is
driven by RIPK1 kinase-dependent cell death (Duprez et al.,
2011) and resembles clinical SIRS (Tracey et al., 1986). Strik-
ingly, cIAP1UBAmut mice were much more sensitive to TNF-
induced SIRS than WT and cIAP2/ counterparts. Accordingly,
following administration of a dose of murine TNF as low as
4 mg/20 g of bodyweight, cIAP1UBAmutmice exhibited a dramatic
drop in body temperature and significant increase in morbidity
(Figures 4A and 4B). TNF-treated cIAP1UBAmut mice also had
significantly elevated levels of aspartate transaminase (AST),
alanine transaminase (ALT), and lactate dehydrogenase (LDH)
in the plasma, indicating liver and tissue damage (Figures 4C
and 4D). Consistently, livers from cIAP1UBAmut mice had higher
numbers of TUNEL-positive cells than cIAP2/ or WT littermate
control mice (Figures 4E and 4F). Collectively, these data
demonstrate that a functional UBA domain in cIAP1 is required
to protect mice from the lethal effects of TNF.
Mutation in theUBADomain Switches theTNFResponse
to Cell Death
Next, we examined the role of the UBA domain in repressing
TNF-induced cell death in primary BMDMs, mouse dermal fibro-
blasts (MDFs), andMEFs. TNF treatment did not induce substan-
tial cell death in either WT or cIAP2-deficient cells; however, it
was a potent cell death stimulus in cIAP1UBAmut cells (Figures
5A, 5C, 5D, S3A, and S3B). This cell death was RIPK1 kinase
dependent because treatment with the selective RIPK1 inhibitor
GSK0963 (Berger et al., 2015) suppressed TNF killing. Likewise,
primary cIAP1UBAmut BMDMs were exquisitely more sensitiveact with TRAF2
rmal titration calorimetry. KD, binding constant. Note the data shown in (A) are
which endogenous cIAP1 was knocked down via inducible expression of
T site that allows Flp-mediated integration of transgenes into the same tran-
0-based shcIAP1 are induced following treatment with doxycycline (Dox). TRE,
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to RIPK1-mediated TNF-induced necroptosis than BMDMs from
either WT littermates or single targeted cIAP2/ animals (Fig-
ure 4A). Consistently, increased association of RIPK1 with
RIPK3 was detected by proximity ligation assay (PLA) (Fig-
ure 5B). Primary MDFs and MEFs instead seemed to die by
apoptosis because RNAi-mediated depletion of MLKL had no
apparent effect on TNF-induced cell death in cIAP1UBAmut
MEFs (Figure S3D). Indeed, TNF stimulation of cIAP1UBAmut
MDFs andMEFs caused elevated levels of caspase activity (Fig-
ure S3E), which was accompanied with enhanced complex-II
formation (Figures 5D and 5F), and cleavage and acti-
vation of caspase-8 and caspase-3 (Figure S3F). Importantly,
cIAP1UBAmut MEFs, prepared from multiple embryos within the
same litter and between litters, behaved in the same manner
(Figures S3A–S3C). Together, these data suggest that the UBA
domain allows cIAP1 to inhibit TNF-induced death.
The UBA Directly Regulates RIPK1 Ubiquitylation
Because ubiquitylation of RIPK1 and other components of com-
plex-I represses RIPK1-dependent formation of complex-II, we
analyzed complex-I formation in MDFs and MEFs. As previously
reported, deficiency of cIAP1 and cIAP2 prevented ubiquitylation
of RIPK1 and the recruitment of the LUBAC components
SHARPIN and HOIL-1 5 min after TNF stimulation (Figure 6A)
(Haas et al., 2009). We found no evidence for defective ubiquity-
lation of RIPK1 in complex-I in single-targeted cIAP2/, but
cIAP1-deficient MEFs had significantly lower molecular weight-
modified forms of RIPK1 and substantial levels of non-modified
RIPK1. cIAP1UBAmut cells, however, displayed a marked and
reproducible decrease in the extent of high molecular weight
RIPK1 ubiquitylation (red arrows) in complex-I in both MEFs
and MDFs (Figures 6A, 6B, and S4A), compared to cIAP2/
and WT cells. Importantly, the extent of non-modified RIPK1 in
complex-I was indistinguishable between WT, cIAP2/, and
cIAP1UBAmut cells (Figures 6A and 6B), suggesting that equiva-
lent amounts of RIPK1 undergo Ub modifications in these three
genotypes. Because the same amount of RIPK1 is being ubiqui-
tylated in WT, cIAP2/, and cIAP1UBAmut cells, but overall ubiq-
uitylation of RIPK1 seems to be affected in cIAP1UBAmut cellsFigure 3. Micewith aKnockinMutation in the UBADomain Develop Nor
NF-kB Activation
(A) Gene targeting strategy for the generation of mice with conditional deletion of
cIAP2 were flanked by FRT sites. To generate the UBA mutation, M396 and F398
lox-P flanked-minigene spanning exon 4 to 7 of cIAP1 followed by a stop sequence
of cIAP1 and therefore the conditional expression of the UBA mutation.
(B) Expected and observed numbers of mice from crosses with the respective g
(C) Western blot analysis of cIAP1 protein levels of WT and cIAP1UBAmut MEFs o
(D) Biotinylated SM was used to purify IAPs from lysates of cIAP2/ and cIAP
parallel, expression levels of cIAP1 and TRAF2 were controlled by immunoblottin
(E) Purification of the TNF-receptor signaling complex (complex-I) from immortaliz
and 60 min. Cell lysates were then subjected to FLAG IP followed by western blot
independent experiments are shown.
(F) Western blot analysis of cIAP2/ and cIAP1UBAmut MEFs treated with SM (10
antibodies.
(G) Western blot analysis of MEFs with the indicated genotypes treated with TNF
(H and I) The presence of relative mRNA levels (H) and cytokines in the culture m
analyzed by RT-PCR and ELISA, respectively. Graphs show mean ± SD; n = 3 in
(J and K) Primary WT and cIAP1UBAmut BMDMs (J) and keratinocytes (K) were t
cytokines were measured by RT-PCR. Graphs show mean ± SD, n = 3 independ
572 Molecular Cell 69, 566–580, February 15, 2018compared to WT and cIAP2/ cells, we conclude that RIPK1
undergoes Ub modifications that are distinct from those
observed in WT, cIAP1/, or cIAP2/ cells. Although the
UBA mutation resulted in reduced levels of ubiquitylated RIPK1
in complex-I, this had no apparent effect on the kinetics of the
recruitment of other components of the TNF-RSC such as
SHARPIN and HOIL-1 (Figures 5A and 5B).
Next, we addressed whether the weakened association of
cIAP1UBAmut with TRAF2 might lead to decreased recruitment
of cIAP1 to complex-I and decreased ubiquitylation mediated
by cIAP1 (Figures 6A and 6B). To this end, we increased the
amount of cIAP1UBAmut to the levels of WT cIAP1 in complex-I
using a doxycycline-inducible reconstitution approach. This
allowed us to induce the expression of cIAP1UBAmut so that a
comparable amount of cIAP1UBAmut protein was present in com-
plex-I as in WT or cIAP2 KO cells (Figure 6C). Even though the
levels of cIAP1UBAmut in complex-I were comparable to cIAP1
WT, this did not ‘‘normalize/correct’’ the ubiquitylation pattern
of RIPK1, nor did it have an impact on the recruitment of unmod-
ified RIPK1 in complex-I (Figure 6C). This demonstrates that the
different smearing pattern of ubiquitylated RIPK1 in cIAP1UBAmut
cells is not due to impaired recruitment of cIAP1 to complex-I,
and, therefore, is not TRAF2 binding dependent but merely
UBA dependent.
A Functional UBA Is Required for Efficient
K48 Ubiquitylation and Degradation of RIPK1 in
Complex-I
To provide a robust analysis of the composition of Ub linkage
types on RIPK1 in cIAP2/ and cIAP1UBAmut cells, we employed
absolute quantification (AQUA)-based mass spectrometry anal-
ysis of Ub chain composition (Ordureau et al., 2015) on complex-
I-derived RIPK1. To this end, we performed two consecutive IPs,
first of complex-I (FLAG-TNF) and then of RIPK1 (Figure 7A), fol-
lowed by AQUA-based absolute quantification of chain types
using mass spectrometry. Our analysis revealed that K48-linked
chains on RIPK1 were reproducibly less abundant (>10% reduc-
tion) in cIAP1UBAmut,cIAP2/ mutant cells compared to cIAP2/
(Figures 7A and S5A). Besides K63-linked Ub chains, no othermally andDoNot Exhibit Defects in theCanonical andNon-canonical
cIAP2 and conditional mutation of the UBA domain of cIAP1. Exon 2 and 3 of
were mutated to A396 and A398, respectively. A targeting vector containing a
and a hygromycin resistance sequencewas used to ensure theWT expression
enotypes.
btained from three different embryos.
1UBAmut MEFs and TRAF2 binding was then assessed by immunoblotting. In
g total cell lysates with the indicated antibodies.
edMEFs. Cells of the indicated genotypes were treatedwith FLAG-TNF for 0, 5,
analysis with the indicated antibodies. Representative images of at least three
0 nM) or TWEAK for 6 hr, followed by western blot analysis using the indicated
and harvested at the indicated times points.
edia (I) of MEFs treated with TNF (10 ng/mL) for the indicated time points were
dependent biological repeats.
reated with TNF (10 ng/mL) for 2 and 6 hr, and mRNA levels of the indicated
ent biological repeats.
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with 4 mg/20 g bodyweight ofmTNF. Data are representative of two independent experiments. Error bars represent SD. Survival curveswere compared using log-
rank Mantel-Cox test (*p < 0.05, ***p < 0.001).
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linkage types were reproducibly detected on RIPK1 in MEFs,
although other groups previously reported the presence of
K11- and M1-linked chains on RIPK1, using different cell types
and conditions (Dynek et al., 2010; Gerlach et al., 2011). Calcu-
lations from the AQUA-based mass spectrometry experiment
indicated that the majority of Ub is conjugated in the form of
mono-Ub moieties rather than chains, and the actual chains on
RIPK1 are surprisingly short, even in the control situation (Fig-
ure S5A). Given that the overall smearing pattern is reduced in
cIAP1UBAmut cells, this suggests not only that K48 ubiquitylation
is affected, but also that the occupancy of Ub-acceptor K resi-
dues is altered.
To study the occupancy of Ub-acceptor lysines of RIPK1, we
analyzed ubiquitylated RIPK1 from complex-I using Ub chain re-
striction (UbiCRest) (Hospenthal et al., 2015) (Figure 7B). To this
end, we used a combination of deubiquitylating enzymes (vOTU/
OTULIN) that remove all chain types but leave the most proximal
Ub attached to RIPK1. vOTU hydrolyzes all Ub-linkage types
except M1-linked chains, which can be cleaved by OTULIN. In-
cubation with vOTU/OTULIN revealed a reduction in the Ub-site
occupancy in cIAP1UBAmut compared to cIAP2/ (Figure 7B).
The reduced Ub occupancy of RIPK1 might help to explain the
shift toward the lower molecular weights of ubiquitylated
RIPK1 in cIAP1UBAmut cells.
Because K48-linked chains as well as poly-mono-ubiquityla-
tion can target proteins for degradation (Lu et al., 2015), we
tested whether the combined reduction in poly- and mono-ubiq-
uitylation of RIPK1 affects the stability of RIPK1 in complex-I. Us-
ing tandem Ub-binding entities (TUBEs) (Hjerpe et al., 2009),
which allow isolation of poly-ubiquitylated proteins, we found
that the levels of ubiquitylated RIPK1 dramatically accumulated
in cIAP1UBAmut cells compared to WT cells over a 6-hr time
period following TNF treatment (Figure 7C). Importantly, TNF-
induced accumulation of ubiquitylated RIPK1 in cIAP1UBAmut
cells coincided with a significant increase in formation of
complex-II and activation of caspase-8 (Figure 7C). This demon-
strates that the UBA domain of cIAP1 represses lethal accumu-
lation of RIPK1, most likely by facilitating efficient poly-mono as
well as K48-mediated ubiquitylation and degradation of RIPK1,
which would lower the number of ‘‘seeding’’ molecules for
formation of complex-II (Jaco et al., 2017). Importantly, while
ubiquitylated RIPK1 accumulated over time in TNF-treated
cIAP1UBAmut cells, treatment of cIAP1UBAmut cells with protea-
some inhibitors (MG132) did not result in a further increase in
RIPK1 accumulation (Figure 7D), corroborating the notion that
the stabilization effect is due to the UBA mutation. In contrast,
proteasome inhibition in WT cells resulted in a substantial accu-
mulation of RIPK1 in the ubiquitylated proteome (Figure S5A),Figure 5. Mutation in the UBA Domain Switches the TNF Response to
(A, C, and E) Primary BMDMs (A), MDFs (C), and MEFs (E) of the indicated genoty
BMDMs TNF 1 ng/mL) for 24 hr followed by quantification of propidium iodide (PI)
statistics were performed using two-way ANOVA.
(B) PLA of primary BMDMs from cIAP2/ and cIAP1UBAmut animals using RIPK1 a
time points. The graph to the side indicates the quantification of RIPK1/RIPK3 P
(D and F) Primary MDFs (D) and MEFs (F) of the indicated genotypes were treated
IP and western blot analysis for the indicated proteins. Images are representa
***p < 0.001.indicating that under normal conditions RIPK1’s stability is
regulated, at least in part, in a Ub- and proteasome-dependent
fashion. Of note, because RIPK1 forms amyloid-like structures
upon activation, the TUBE-based experiment also purifies non-
ubiquitylated RIPK1 that is bound to ubiquitylated RIPK1. More-
over, using a broad-spectrum DUB inhibitor (PR619), we found
no evidence for a role of the UBA domain in shielding ubiquity-
lated RIPK1 from DUB digestion (Figures S5B and S5C).
UBA-Dependent Ubiquitylation of RIPK1 Represses Its
Kinase Activity
TNF-induced activation of IKK and MK2 directly suppresses the
kinase activity and cytotoxic potential of RIPK1 (Dondelinger
et al., 2015, 2017; Jaco et al., 2017; Menon et al., 2017). In partic-
ular, MK2 directly phosphorylates mouse RIPK1 at serine (S)321
and S336 (S320 and S335 in human), which in turn suppress
RIPK1 auto-activation at S166 (Dondelinger et al., 2017; Jaco
et al., 2017; Menon et al., 2017). Because cIAP1UBAmut cells
are sensitized to RIPK1 kinase-mediated cell death in response
to TNF, we addressed whether the UBA mutation affects MK2-
mediated suppression of RIPK1 kinase activity. RIPK1 IP from
TNF-treated cIAP2/ and cIAP1UBAmut cells revealed a strong
increase in auto-phosphorylation at S166 in cIAP1UBAmut cells,
which is entirely consistent with the notion that TNF causes
auto-activation of RIPK1 and RIPK1 kinase-dependent cell
death in these cells (Figure 7E). However, activation of MK2
and MK2-mediated phosphorylation of S321 appeared normal
in cIAP1UBAmut cells, demonstrating that activation of RIPK1
kinase activity in cIAP1UBAmut cells was MK2 independent. Acti-
vation of IKK and NF-kB-mediated expression of target genes
was equivalent in WT, cIAP2/, and cIAP1UBAmut cells (Figures
3G–3J), suggesting that IKK-mediated regulation of RIPK1 was
not perturbed in cIAP1UBAmut cells. Consistent with this view,
we find that inhibition of IKK with TPCA-1 further sensitized
cIAP1UBAmut cells to TNF killing (Figure 7F). Together, our data
are consistent with a model whereby cIAP1 regulates RIPK1 ki-
nase activity not only by activating downstream kinases, such
as IKK andMK2, but also by directly repressing RIPK1 kinase ac-
tivity via Ub-dependent inactivation.
DISCUSSION
Ub-mediated inactivation of RIPK1 has long been postulated to
contribute to the regulation of cytokine-induced cell death (Ea
et al., 2006; Moquin et al., 2013; O’Donnell et al., 2007). How-
ever, detailed insights into the determinants and the actual mo-
lecular and functional consequences of RIPK1 ubiquitylation
have not been demonstrated. Here, we show that the UBACell Death
pes were treated as shown (TNF 100 ng/mL, GSK0963 100 nM, SM 100 nM, for
-positive cells. Data are presented as mean ± SD, n > 3, *p < 0.05, ***p < 0.001;
nd RIPK3 antibodies. Cells were stimulated with 1 ng/mL TNF for the indicated
LA speckles. The graph shows mean ± SD.
for 4 hr as indicated (TNF 100 ng/mL, z-VAD-FMK 10 mM), followed by FADD
tive of three independent experiments. Graphs show mean ± SD, *p < 0.05,
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Figure 6. The UBA Directly Regulates RIPK1 Ubiquitylation
(A and B) Purification of the TNF-R1 signaling complex (complex-I) from pri-
mary MEFs (A) and MDFs (B). Cells of the indicated genotypes were treated
with FLAG-TNF for 0, 5, and 60 min. Cell lysates were then subjected to FLAG
IP followed by western blot analysis with the indicated antibodies. Repre-
sentative images of three independent experiments are shown.
(C) Purification of the TNF-R1 signaling complex (complex-I) from immortalized
cIAP2/ and cIAP1UBAmut MEFs reconstituted either with empty vector
(control) or a doxycycline-inducible construct encoding cIAP1UBAmut.
576 Molecular Cell 69, 566–580, February 15, 2018domain of cIAP1 interacts with TRAF2 and is required for proper
regulation of RIPK1 kinase activity. In the absence of a functional
UBA domain, more active RIPK1 kinase accumulates in
response to TNF, causing RIPK1 kinase-mediated cell death
and systemic inflammatory response syndrome.
UBA-dependent ubiquitylation of RIPK1 seems to regulate
RIPK1 kinase activity through two potentially interconnected
mechanisms: first, the UBA contributes to optimal Ub occu-
pancy of RIPK1. This is evident as fewer lysine residues are con-
jugated to Ub in cells from cIAP1UBAmut animals. While this
reduction in ubiquitylation of RIPK1 has no effect on its scaf-
folding function, such as activation of TAK1, IKK, MK2, and
NF-kB, and the production of cytokines, reduced RIPK1 ubiqui-
tylation compromises regulation of RIPK1 kinase activity, leading
to enhanced RIPK1 auto-phosphorylation and formation of com-
plex-II. Second, the UBA domain of cIAP1 also influences the
cytotoxic potential of RIPK1 by targeting it for proteasomal
degradation.
Although the overall difference in K48 ubiquitylation of RIPK1
5 min after TNF treatment was reproducibly small, this causes
a significant alteration of RIPK1’s stability as active, ubiquity-
lated RIPK1 accumulates over time in cIAP1UBAmut cells. Multiple
Ub modifications, which include short Ub chains, constitute a
powerful degradation signal (Lu et al., 2015). Hence, it is likely
that the combined reduction in poly- and mono-ubiquitylation
of RIPK1 ultimately contributes to the increased protein stability
of RIPK1 in complex-I from cIAP1UBAmut cells, leading to exacer-
bated RIPK1 kinase activity in response to TNF. Thus, under
normal conditions, the conjugation of Ub to RIPK1might impede
its auto-activation and, in addition, mark it for proteasomal
degradation, thereby limiting accumulation of cytotoxic RIPK1.
Nevertheless, cIAP1 clearly also suppresses the cytotoxic po-
tential of RIPK1 in a UBA-independent manner. Thus, cIAP1
also represses RIPK1 auto-activation by facilitating Ub-medi-
ated recruitment of LUBAC, and activation of IKK and MK2.
This enables IKK- and MK2-mediated regulation of RIPK1 via
inhibitory phosphorylation (Dondelinger et al., 2015, 2017; Jaco
et al., 2017; Menon et al., 2017). Our current data are consistent
with a revised model for TNF signaling whereby RIPK1’s kinase
activity is suppressed through both Ub-mediated phosphoryla-
tion of RIPK1 by IKK and MK2 as well as by direct Ub-mediated
inactivation and degradation of RIPK1. However, we cannot
formally exclude the possibility that the UBA also enables the
recruitment of a yet to be identified kinase, which might repress
RIPK1.
Unexpectedly, we find that the UBA domain of cIAP1 contrib-
utes to efficient TRAF2 binding. Consistent with the notion that
cIAP1 interacts with TRAF2 through a multivalent interaction
via its BIR1 as well as UBA domain, we find that point mutations
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in either the BIR1 or UBA domain weaken the interaction
between cIAP1 and TRAF2. Although cIAP1UBAmutant proteins
bind less well to TRAF2 in coIP studies under resting conditions,
under in vivo settings this association is sufficient to maintain
TNF-induced activation of NF-kB or support TRAF2/TRAF3-
mediated degradation of NIK. Importantly, despite the fact that
UBA mutant cIAP1 interacts less efficiently with TRAF2 under
IP conditions, the reduced ubiquitylation of RIPK1 in complex-I
observed in cIAP1UBAmutant cells is not due to impaired cIAP1
recruitment. This is evident as elevating the recruitment of
cIAP1UBAmut into complex-I does not ‘‘normalize/correct’’ the
ubiquitylation pattern of RIPK1. Further evidence is provided
by the fact that the UBA mutation of cIAP1 does not phenocopy
loss of TRAF2. Accordingly, RIPK1 is readily ubiquitylated in
complex-I in cells from cIAP1UBAmut animals. In contrast,
RIPK1 ubiquitylation in complex-I is completely lost in Traf2/
cells. Taken together, our data demonstrate that cIAP1UBAmut re-
tains E3 ligase activity, and the UBA domain is dispensable for
embryonic development, routine tissue homeostasis, or NF-kB
regulation. Thus, the elevated sensitivity to the cytotoxic poten-
tial of TNF cannot be explained by the regulation of NF-kB, IKK,
or MK2. We propose that the UBAmutation provides rare insight
into the protein architecture of complex-I. We suggest that the
UBA contributes to the proper positioning of the RING domain
of cIAP1 within complex-I so that the Ub-loaded E2 enzyme
can optimally transfer ubiquitin to RIPK1.
As TNF is a key player in the cytokine network that supports
inflammation-associated cancer and cancer-related inflamma-
tion (Mantovani et al., 2008), it will be important to gain a better
understanding of the checkpoints that control life and death de-
cisions in response to TNF. A better understanding of such
checkpoints could lead to new approaches for the treatment of
chronic inflammatory diseases that are fueled by aberrant
RIPK1-induced cell death, and/or reveal novel strategies for
anti-cancer immunotherapies that harness RIPK1’s ability to
trigger immunogenic cell death (Yatim et al., 2015).STAR+METHODS
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Anti-GR-1-PE-Cy7 eBioscience A14748
Anti-CD11c-FITC eBioscience 11-0116-41
Anti-CD4-FITC eBioscience MCD0401
Anti-CD11b-Cy5 eBioscience 53-0112-82
Anti-B220-FITC eBioscience 11-0460-82
Anti-CD69-PE eBioscience 12-0691-82
Anti-CD3-APC eBioscience 47-0032-82
Anti-CD16 eBioscience 14-0161-82
Chemicals, Peptides, and Recombinant Proteins
Mouse recombinant TNF Enzo Life Sciences ALX-522-009-C050
OTULIN In house N/A
vOTU In house N/A
USP21 In house N/A
PR619 2B Scientific SI9619
GSK’963 (RIPK1 inhibitor) Gift from GSK N/A
GST-TUBE In house N/A
Glutathione Sepharose 4B GE Healthcare 17-0756-01
cOmplete EDTA-free protease inhibitor tablets Roche 11873580001
3xFLAG-hTNF In house N/A
Anti-FLAG M2 Affinity Gel Sigma A2220
1x FLAG-TNF Enzo Life Sciences ALX-804-034-C050
(Continued on next page)
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REAGENT or RESOURCE SOURCE IDENTIFIER
zVAD-FMK Apex Bio A1902
Protein G Sepharose Sigma P3296
Hoechst Thermo Scientific 33342
Propidium iodide solution Sigma P4864
Various recombinant human cIAP2 and TRAF2 segments In house N/A
ULP1 protease In house N/A
Ac-DEVD-AMC Sigma A1086
3-AT Formedium 3AT010
PreScission GE Healthcare 27-0843-01
Compound A (Smac mimetic) TetraLogic Pharmaceuticals N/A
MG132 Sigma C2211
Biotinylated SM Gift from X. Wang N/A
(5Z)-7-Oxozeaenol (TAK1 inhibitor) Tocris Bioscience 3604
TWEAK Enzo 522-021-c10
Critical Commercial Assays
Duolink In Situ Detection Reagents Green Sigma DUO92014
Deposited Data
Raw data Mendeley https://doi.org/10.17632/f559yfv4h4.1
Experimental Models: Cell Lines
Primary MEFs WT, cIAP2/cIAP1/, cIAP2/,
cIAP2/and cIAP2/cIAP1UBAmut
In house N/A
Primary MDFs WT, cIAP2/ and cIAP2/cIAP1UBAmut In house N/A
Primary BMDMs WT, cIAP2/ and cIAP2/cIAP1UBAmut In house N/A
Primary Keratinocytes WT and cIAP2/cIAP1UBAmut In house N/A
Primary Splenocytes WT and cIAP2/cIAP1UBAmut In house N/A
Flp-InTMT-RExTM-HEK293 Thermo Scientific R78007
Experimental Models: Organisms/Strains
Mouse: C57BL/6 cIAP2/cIAP1loxP/loxP Gift from John Silke N/A
Mouse: C57BL/6 cIAP2FRT/FRTcIAP1minigene In house N/A
Mouse: C57BL/6 cIAP2/cIAP1minigene In house N/A
Mouse: C57BL/6 cIAP2/cIAP1UBAmut In house N/A
Recombinant DNA
pTRIPZ GE Dharmacon RHS4696
pTRIPZ-shcIAP1 Open Biosystems N/A
pCDNA5.5/FRT/TO vector Thermo Fisher Scientific V652020
pOG44 Thermo Fisher Scientific V600520
pGBT9 Clontech/Takara N/A
pACT2 Clontech/Takara N/A
pGEX6P-1 GE Healthcare N/A
Software and Algorithms
Image Lab V5.2.1. Bio-Rad laboratories N/A
Origin MicroCal N/A
Swiss-Prot https://www.ebi.ac.uk/uniprot N/A
GraphPad Prism v6.0 https://www.graphpad.com/ N/ACONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for reagents may be directed to and will be fulfilled by the Lead Contact, Pascal Meier (pmeier@icr.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice generation
The cIAP2 and cIAP1 genes are positioned 10 Kb apart on the same chromosome. Hence, they recombine as a single genomic locus.
The cIAP2FRT/FRTcIAP1minigenemousewas generated by electroporating the cIAP1 targeting vector intoC57BL6-derived ES cells that
were previously targeted on the cIAP2 locus (Moulin et al., 2012). For the cIAP1 targeted allele the M396A and F398Amutations were
introduced into exon 4 and a F3 site-flanked PGK-Hygro selection cassette was inserted upstream of the genetically altered exon 4. A
mini-gene corresponding to exon 4-7 of cIAP1 and a BGH poly-A signal were placed upstream of the selection cassette. The cDNA
mini-gene is flanked by loxP sites. Mice carrying the cIAP2FRT/FRTcIAP1minigene alleles were crossed to transgenic mice expressing
the FLPo recombinase to generate the cIAP2/cIAP1minigene animals. The PGK-Hygro resistance cassette on the cIAP1 targeted
allele was also deleted by the FLPo-mediated recombination. The cIAP2/cIAP1minigene mice were subsequently crossed to
transgenic mice expressing the Cre recombinase to delete the mini-gene and generate the cIAP2/cIAP1UBAmut animals.
cIAP2/cIAP1loxP/loxP mice were previously described (Moulin et al., 2012). Mice were kept according to the UK Home Office reg-
ulations. In vivo experiments were conducted according to institutional, national and European animal regulations. Animal protocols
were approved by the Ethics Committee of Ghent University.
Mice injections monitoring and sampling
Experiments in mice were performed at the Department of Pharmacology of the Faculty of Veterinary Medicine of the Ghent Univer-
sity, Belgium, according to institutional, national and European regulations. Animal protocols were approved by the ethics committee
of Ghent University. mTNF was diluted in endotoxin-free PBS and injected intravenously (i.v.) in a volume of 0.2 ml. Rectal body tem-
perature was recorded with a digital thermometer (model 2001; Comark Electronics). Plasma samples and tissue samples of liver
were collected at designated times after injection. Blood was obtained by cardiac puncture.
Cell lines
Primary and immortalizedMEFs, primaryMDFs and Flp-InTM-RexTM-HEK293 cells were cultured in Dulbecco’s modified Eagle’sMe-
dium (DMEM) supplemented with 10% Fetal Bovine Serum (FBS), penicillin and streptomycin under 10% CO2.
METHOD DETAILS
Isolation of primary cells
Primary Mouse Embryonic Fibroblasts (MEFs) were generated from E13.5 embryos. After removing the placenta, yolk sac, head and
the dark red organs, embryos were finely minced and digested for 20 min in 0.25% trypsin. Single cell suspension was then obtained
by pipetting up and down the digested embryos. Mouse Dermal Fibroblasts (MDFs) were isolated as described in Etemadi et al.
(2015). To generate Bone Marrow Derived Macrophages (BMDMs), bone marrow cells from tibia and femur of 2 month old mice
were seeded in non-coated Petri dishes and cultured for 6 days in Dulbecco’s modified Eagle medium + 10% fetal bovine serum +
20% (v/v) L929 mouse fibroblast conditioned medium. Keratinocytes were isolated as described in Lichti et al. (2008). Splenocytes
were isolated from 2month oldmice. Mouse spleens weremashed through a cell strainer into the Petri dish using the plunger end of a
syringe. Cells were then washed once in cold PBS and treated with 1X Red Blood Cell Lysis Buffer (BioLegend, Cat N 420301) for
5 min on ice. Cells were then washed again in PBS and counted.
Splenocytes FACS analysis
5 3 105 splenocytes were resuspended in 500 mL of cold PBS and stained with DAPI (1/5000) for 20 min on ice. Cells were then
washed with cold PBS and resuspended in 50 mL Staining Buffer. 2 mL of blocking antibody (Anti-Mouse CD16/CD32) were added,
and cells were kept on ice for 10 min. 50 mL of Staining Buffer containing the desired antibodies were then added and cells were kept
on ice for 30 min. Cells were washed in cold PBS, resuspended in 1 mL of cold PBS and analyzed by FACS.
Cell culture, constructs and transfection
For the generation of the 293 stable cell lines, where endogenous cIAP1 was reconstituted with WT and mutant cIAP1, Flp-InTM T-
RExTM HEK293shcIAP1 cells were created. First Flp-InTMT-RExTM-HEK293 cells (Invitrogen) were transduced with lentiviral particles
targeting the 30 UTR of the cIAP1mRNA. To this end, we used pTRIPZ-shcIAP1 (Open Biosystems), which allows Doxocycline-induc-
ible expression of a miR30-based shcIAP1 RNA. After puromycin selection, individual clones were tested for cIAP1 knockdown ef-
ficiency. Such cells were further tested functionally using TNF signaling and NIK activation as readouts. Next, the respective cIAP1
constructs were cloned into pcDNA5.1/FRT/TO (Invitrogen). The empty pcDNA5.1/FRT/TO-2HA-Strep plasmid was used as a con-
trol. To generate site-specific single copy insertions, pcDNA5.1FRT/TO-based plasmids were co-transfected with pOG44 into Flp-
InTMT-RExTM-HEK293shcIAP1 cells. After selection with hygromycin, stable cells were selected. Endogenous cIAP1 suppression and
expression of WT or mutant versions of cIAP1 were simultaneously induced by treating cells with 100 ng/ml Doxycycline for at least
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Reagents, Constructs and Antibodies
The GSK’963 RIPK1 kinase inhibitor was provided by GSK. The following antibodies were used: a-RIPK1 (BD Biosciences, 610459),
a-HOIL (gift from Henning Walczak), a-cIAP1 (Enzo, ALX-803-335-C100), a-TNFR1 (Abcam, 19139), a-Actin (Santa Cruz Biotech-
nology, sc-1615), a-P-p65 (Cell Signaling, 3033), a-p65 (Cell Signaling, 8242), a-IkBa (Santa Cruz, sc-371), a-P-p38 (Cell Signaling,
9215), a-p38 (Cell Signaling, 9212), a-P-JNK (Cell Signaling, 9255), a-JNK (Santa Cruz Biotechnology, sc-571), a-P-ERK
(Cell Signaling, 9101), a-ERK (gift from Chris Marshall) a-caspase-8 (Cell Signaling, 9429), a-FLAG [M2] (SIGMA, M8823), a-Ub
(Dako, Z0458), a-FLIP (Adipogene, AG-20B-0056), a-FADD (Santa Cruz Biotechnology, sc-6036), a-RIPK3 (ProSci, 2283), a-Tubulin
(SIGMA, T9026), a-SHARPIN (Proteintech, 14626-1-AP), a-TRAF2 (Cell Signaling, 4712), a-CD8-PE-Cy7, GR-1-PE-Cy7, CD11c-
FITC, CD4-FITC, CD11b-Cy5, B220-FITC (gift from Henning Walczak), a-CD69-PE (eBioscience, 12-0691-82), a-CD3-APC
(eBioscience, 47-0032-82), and a-CD16 (eBioscience, 14-0161-82).
UbiCRest analysis
The UbiCRest analysis with linkage selective DUBs was performed essentially as described in Hospenthal et al. (2015). Briefly, the
release fraction (see complex-I purification) was incubated with the following DUBs: 1 mMOTULIN, 0.5 mMvOTU, 1.5 mMUSP21. The
reaction was conducted in the presence of 1 mM DTT for 30 min at 37C. Reactions were stopped with SDS sample buffer, and
the ubiquitylation status analyzed by western blotting.
Tube Assay
Cells were lysed in DISC lysis buffer (20 mM Tris-HCL pH7.5, 150 mM NaCl, 2 mM EDTA, 1% Triton X-100, 10% glycerol) supple-
mented with protease inhibitors, 1 mM DTT, PR619 (10 mM) and GST-TUBE (50 mg/ml; 50 mg TUBE/mg protein lysate). Cell lysates
were rotated at 4C for 20min then clarified at 4C at 14,000 rpm for 10min. 20 mL GST beads were added and immunoprecipitations
were performed overnight. Beads were washed 4x in wash buffer (50 mM Tris pH 7.5, 150 mM NaCl, 0.1% Triton X-100, and 5%
glycerol) + PR619 (10 mM), and bound proteins eluted by boiling in 50 m l 1x SDS loading dye.
Complex-I/II Purification
Cells were seeded in 15 cm dishes and treated as indicated with 3x FLAG-hTNF (5 mg/ml). To terminate stimulation, media was
removed and plates were washed with 50 mL of ice cold PBS. Plates were frozen at80C until all time points were acquired. Plates
were thawed on ice and cells were lysed in 1% Triton X-100 lysis buffer (30 mM Tris-HCl pH 7.4, 120 mM NaCl, 2 mM EDTA, 2 mM
KCl, 10% glycerol and 1% Triton X-100, supplemented with protease inhibitors and PR619 (10 mM). Cell lysates were rotated at 4C
for 20 mins then clarified at 4C at 14,000 rpm for 30 mins. Proteins were immunoprecipitated from cleared protein lysates with 20 mL
of a-FLAG M2 beads (SIGMA) with rotation overnight at 4C. For the 0 hr sample 5 mg/ml of FLAG-TNF were added post-lysis.
4x washes in 1% Triton X-100 buffer with PR619 (10 mM) were performed, and samples eluted by boiling in 60 mL 1x SDS loading
dye. For complex-II purification cells were seeded in 10 cm dishes and treated as indicated using media containing 1x FLAG-TNF
(100 ng/ml) and zVAD (10 mM). Cells were lysed on ice in 1% Triton X-100 lysis buffer (30 mM Tris-HCL pH 7.4, 120 mM NaCl,
2 mM EDTA, 2 mM KCl, 1% Triton X-100 supplemented with protease inhibitors and 10 mM PR619). Cell lysates were rotated at
4C for 20 mins then clarified at 4C at 14,000 rpm for 10 mins. 20 mL of protein G Sepharose (SIGMA), blocked for 1 hr with lysis
buffer containing 1%BSA, were boundwith FADD antibody (1.5 mg antibody/mg protein lysate) andwere rotated with cleared protein
lysates 4 hr at 4C. 4x washes in lysis buffer were performed, and samples eluted by boiling in 80 mL 1x SDS sample buffer.
Cell death analysis
2 3 105 cells (MEFs and MDFs) were seeded in six well plates and 24 hr later they were treated as indicated for an additional 24 hr.
Hoechst 33342 (10 mg/ml) and Propidium Iodide (PI) (1 mg/ml) were added. After 2 mins 10 to 15 images per well were taken with a
fluorescent inverted microscope and the ration of dead/live cells were counted manually. 5 3 104 BMDMs were seeded in 96 well
plates and 24 hr later they were treated as indicated for an additional 24 hr. Hoechst (0.5 mg/ml) and PI (1 mg/ml) were added and
the ratio dead/live cells was measured using the Celigo imaging system.
Production of recombinant proteins and isothermal titration calorimetry
Various human cIAP2 and TRAF2 segments were cloned into pSUMO vector respectively to produce N-terminally His-SUMO tagged
proteins. The constructs were then transformed into BL21 (DE3) cells and cultured in LB medium at 37C, respectively. Protein
expression was induced overnight at 20C with 0.5 mM IPTG when OD600 reached 0.8. Cells were lysed in buffer containing
25 mM Tris-HCl at pH 8.0, 150 mM NaCl, 10 mM imidazole and 5 mM b-mercaptoethanol. The recombinant proteins were affin-
ity-purified by Ni-Sepharose beads (GE Healthcare Life Sciences). The SUMO tag was removed by overnight digestion with home-
made ULP1 protease at 4C. The untagged proteins were further purified by HiTrap Q anion exchange and Superdex 200 gel filtration
chromatography (GE Healthcare Life Sciences). Isothermal titration calorimetry measurements were performed at 16C, using a
MicroCal ITC200 microcalorimeter (MicroCal). For the TRAF2:cIAP2 interactions, the calorimetric titrations were performed by inject-
ing 2 mL of cIAP2 protein solution (2–4 mM) into a sample cell containing 200 ml 0.20 mM TRAF2 protein in 25 mM Tris-HCl at pH 8.0,
150 mM NaCl. A total of 20 injections were performed with a spacing of 150 s and a reference power of 6 mcal/s. Binding isotherms
were plotted and analyzed using Origin Software (MicroCal).e4 Molecular Cell 69, 566–580.e1–e5, February 15, 2018
Caspase activity assay (DEVDase)
23 105 cells (MEFs) were plated in 6-well plates and treated as indicated in 2 mL for the indicated times. After treatment, media was
removed, and 300 mL 1%DISC lysis buffer (20 mM Tris-HCL pH 7.5, 150 mMNaCl, 2 mM EDTA, 1% Triton X-100, 10% glycerol) was
added to each well, cells were scraped and lysates were left on ice for 5 min. 50 mL of lysate per condition were transferred into a
24 well plate and 450 mL DEVDase assay mix (20 mM Ac-DEVD-AMC (Sigma), 1 mM DTT, 50 mM Tris pH 7.5, 150 mM NaCl,
0.1% Triton X-100, and 5% glycerol) was added to each well (NB: cell lysates were not cleared). Plates were wrapped in foil and re-
actions allowed to proceed by incubation at room temperature for up to 24 hr. DEVDase activity was read at 380 nM excitation/
460 nM emission.
Yeast two- and three-hybrid
The yeast strain Y2HGold (Clontech) was co-transformed with the respective bait and prey plasmids. Positive transformants were
selected onminimal SD-Leu-Trp medium (Formedium). Three single colonies for each bait and prey co-transformation were patched
out on fresh SD-Leu-Trp plates and grown for 2 days at 30C. Each patchwas resuspended in 180 mL of sterile water in a 96-well plate
and replica plated onto non-selective (SD-Leu-Trp) or selective medium (SD-Leu-Trp-His), containing the indicated concentration of
3-amino-1,2,4-triazole (3-AT, Formedium). Yeast plates were incubated at 30C for 1 week. UbcH5b prey vector was provided by
Rachel Klevit.
Protein expression and purification
BL21 cells were transformedwith pGEX6p-1-3XFLAG-TNF plasmid. One colony was picked and incubated o/n in 100mL LBmedium
with 100 mg/ml ampicillin. Next day 900mL of LBmediumwithout AMPwere added, cells were grown for 1 h at 37C and then 0.5mM
IPTGwas added for further 4 h. Bacteria were spun for 15min at 4000 rpm, the supernatant was discarded and the pellet was lysed in
10mL Triton X-100 lysis buffer (10mMTris pH 7.5, 150mMNaCl, 10% glycerol and 1%Triton X-100with complete protease inhibitor
cocktail). The lysate was sonicated and left for 15 min at 4C and clarified for 30 min at 140,000 rpm at 4C. Lysate was rotated with
glutathione Sepharose beads for 4 hr at 4C and 3x washed with IPPG150 buffer (0,1% Triton X-100, 50 mM Tris pH 7.5, 150 NaCl,
5% glycerol) were performed, followed by a final wash in PreScission cleavage buffer (50 mM Tris pH 7, 150 mM NaCl, 1 mM EDTA
and 1mMDTT). For PreScission cleavage 500 mL cleavage buffer and 30 mL PreScission enzymewere added to the beads at 4Co/n.
The beads were spun, and supernatants were collected and passed through Thermo Scientific buffer exchange columns to remove
bead contamination. Recombinant TNF concentration was determined on Coomassie Blue-stained polyacrylamide gel using known
amount of BSA as standard, and quantitated using Image Lab software.
Proximity ligation assay (PLA)
PLA was performed according to the manufacturer’s protocol using the Duolink Detection Kit (SIGMA). Cells were examined with a
confocal microscope (Objective 40x, Zeiss LSM 710).
Ub Chain Composition Mass Spectrometry Analysis
Ub chains were separated on aNuPAGE 4%–12%gradient gel (Invitrogen) before in-gel digestionwith trypsin and the addition of Ub-
AQUA peptide internal standards according to Kirkpatrick et al. (2006). 10 mL of each sample was directly injected onto an EASY-
Spray reverse-phase column (C18, 3 mm, 100 A˚, 75 mm3 15 cm) using a Dionex UltiMate 3000 high-pressure liquid chromatography
system (Thermo Fisher Scientific) and analyzed on a Q-Exactive mass spectrometer (Thermo Fisher Scientific) using parallel reaction
monitoring (PRM), similar to Tsuchiya et al. (2013). Data were analyzed further according to Kirkpatrick et al. (2006)
DATA AND SOFTWARE AVAILABILITY
Raw data have been deposited to Mendeley Data and are available at https://doi.org/10.17632/f559yfv4h4.1.Molecular Cell 69, 566–580.e1–e5, February 15, 2018 e5
